The randomized phase III LAURA trial was conducted to formally evaluate the safety and efficacy of osimertinib consolidation vs. the placebo after cCRT for unresectable EGFR-mutant NSCLC [31]. Here, EGFR is linked to non-small cell lung carcinoma.